Skip to content

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. Le Beau, Pierre Fenaux, Pierre Morel, Guillermo Francisco Sanz, Miguel Ángel Sanz, Teresa Vallespí, Terry John Hamblin, David Graham Oscier, Kazuma Ohyashiki, Keisuke Toyama, Carlo Aul, Ghulam Jeelani Mufti, John M. Bennett

Blood · 1997 · 4,428 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Greenberg, P. L., Cox, C., Beau, M. M. L., Fenaux, P., Morel, P., Sanz, G. F., Sanz, M. Á., Vallespí, T., Hamblin, T. J., Oscier, D. G., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. J., & Bennett, J. M. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89(6), 2079–2088. https://doi.org/10.1182/blood.v89.6.2079

In text: (Greenberg et al., 1997)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to improve on these systems, an International MDS Risk Analysis Workshop combined cytogenetic, morphological, and clinical data from seven large previously reported risk-based studies that had generated prognostic systems. A global analysis was performed on these patients, and critical prognostic variables were re-evaluated to generate a consensus prognostic system, particularly using a more refined bone marrow (BM) cytogenetic classification. Univariate analysis indicated that the major variables having an impact on disease outcome for evolution to acute myeloid leukemia were cytogenetic abnormalities, percentage of BM myeloblasts, and number of cytopenias; for survival, in addition to the above, variables also included age and gender. Cytogenetic subgroups of outcome were as follows: "good" outcomes were normal, -Y alone, del(5q) alone, del(20q) alone; "poor" outcomes were complex (ie, > or = 3 abnormalities) or chromosome 7 anomalies; and "intermediate" outcomes were other abnormalities. Multivariate analysis combined these cytogenetic subgroups with percentage of BM blasts and number of cytopenias to generate a prognostic model. Weighting these variables by their statistical power separated patients into distinctive subgroups of risk for 25% of patients to undergo evolution to acute myeloid leukemia, with: low (31% of patients), 9.4 years; intermediate-1 (INT-1; 39%), 3.3 years; INT-2 (22%), 1.1 years; and high (8%), 0.2 year. These features also separated patients into similar distinctive risk groups for median survival: low, 5.7 years; INT-1, 3.5 years; INT-2, 1.2 years; and high, 0.4 year. Stratification for age further improved analysis of survival. Compared with prior risk-based classifications, this International Prognostic Scoring System provides an improved method for evaluating prognosis in MDS. This classification system should prove useful for more precise design and analysis of therapeutic trials in this disease.

  1. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report2014
  2. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants2002

Metadata from OpenAlex (CC0). Citations are generated from the published record.